Trials / Completed
CompletedNCT05175352
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
A Phase 1, Open-label, Single-sequence Study to Evaluate Potential Disease-mediated Drug-drug Interaction With Selected Cytochrome P450 Substrates in Adult Subjects With Active Eosinophilic Esophagitis Receiving Cendakimab
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cendakimab | Specified dose on specified days |
| DRUG | CYP substrates | Specified dose on specified days |
Timeline
- Start date
- 2022-06-07
- Primary completion
- 2024-10-11
- Completion
- 2024-10-11
- First posted
- 2022-01-03
- Last updated
- 2024-12-20
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05175352. Inclusion in this directory is not an endorsement.